on ABL DIAGNOSTICS (EPA:ABLD)
ABL Texcell Diagnostics Reduces Resources in its Liquidity Contract
On September 18, 2026, ABL Texcell Diagnostics, a company specializing in innovative molecular biology tests, announced a reduction in the resources allocated to its liquidity contract managed by Invest Securities. This reduction amounts to €50,000 in cash, aimed at rebalancing available resources.
Following this reduction, the liquidity contract balance stands at 27,852 shares and €43,873.58 in cash. By comparison, as of June 30, 2026, the liquidity contract held 33,993 shares and €76,654.75 in cash. This adjustment reflects the company's ongoing efforts to maintain an optimal level of liquidity.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABL DIAGNOSTICS news